Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Primary Industries
- Drugs
- Therapeutic
- Pharmaceuticals
- Disease
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 29443
License Grant
The Company has a collaboration with the Licensor, a subsidiary of Johnson & Johnson, for dapoxetine. In addition, J&J received a not-approvable letter from the FDA in October 2005, but has continued the global development program and stated that it anticipates resubmitting the NDA with the FDA in 2007.
License Property
Dapoxetine is a short-acting selective serotonin reuptake inhibitor (SSRI) marketed for the treatment of premature ejaculation in men.
Field of Use
The rights granted apply to the healthcare industry relating to men.
IPSCIO Record ID: 27826
License Grant
Pursuant to the Development Agreement, Licensor has granted Licensee certain intellectual property licenses related to, among other things, a pharmaceutical composition known as Dapoxetine. As permitted by the Development Agreement, Licensee has sublicensed to Alza, Corporation (Alza) certain rights to develop and market Dapoxetine in exchange for which Licensee is entitled to receive certain milestone, royalty and other payments from Alza. The parties now desire to, among other things, (i) terminate the Development Agreement.
License Property
“Compounds†means those compounds other than Dapoxetine covered by a Valid Claim within the scope of the Licensed Patents.
Dapoxetine is acompound developed specially for the treatment of premature ejaculation (PE) in men 18–64 years old. Dapoxetine works by inhibiting the serotonin transporter, increasing serotonin's action at the post synaptic cleft, and as a consequence promoting ejaculatory delay. As a member of the selective serotonin reuptake inhibitor (SSRI) family, dapoxetine was initially created as an antidepressant.
Field of Use
Field shall mean all therapeutic indications for use in humans (i.e. specifically excluding use in animals) within the urogenital area, including primary urinary incontinence, urge, stress and mixed incontinence, urinary urgency, interstitial cystitis, neurogenic bladder, bladder sphincter dyssynergia and irritative symptoms of benign prostate hypertrophy, hypoactive sexual desire, hyperactive sexual desire, impotence, retarded ejaculation, premature ejaculation, delayed
orgasm and anorgasmia.
IPSCIO Record ID: 25852
License Grant
The Licensee acquired patents covering Priligy from the Licensor.
License Property
Under the terms of the 2012 License Agreement with Menarini, Menarini will pay the royalties owed to the Licensor in each country where the Licensor is eligible for payments, but the Licensee is no longer eligible for payments from Menarini.
Priligy is a compound for the treatment of premature ejaculation (PE) in men 18-64 years old.
Field of Use
The Field of Use apply to the healthcare industry.
The Licensee is obligated to pay the Licensor a royalty on annual sales in excess of $800.0 million.
IPSCIO Record ID: 25933
License Grant
In December 2003, the Licensee acquired the Licensor's patents and remaining rights to develop and commercialize dapoxetine in the field of genitourinary disorders.
Field of Use
The rights granted apply tot he drug development market.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
